Denmark's ChemoMetec Q3 revenue rises

ChemoMetec A/S

06/05/2026 18:02

Overview

Denmark cell counting instrument maker's Q3 revenue up 15% yr/yr

Q3 EBITDA rose 33% yr/yr, or 9% excluding one-off effect

Sales of XcytoMatic instruments more than quadrupled, excluding one-off effect

Outlook

Chemometec maintains 2025/26 revenue guidance at DKK 505-525 mln

Company keeps 2025/26 EBITDA forecast at DKK 275-290 mln

Chemometec says macroeconomic and geopolitical uncertainty continues to impact its markets

Result Drivers

XCYTOMATIC INSTRUMENTS - Growth in sales of XcytoMatic products, including the NC-203, was a key driver of Q3 results as customers increased automation of workflows

CONSUMABLES DECLINE - Sales of consumables fell 10% in Q3, mainly due to fewer active clinical trials, fewer patients treated, and major players exiting the cell and gene therapy market

BUSINESS SHIFT - Sales in animal semen, beer and milk segment dropped 50% as Chemometec deprioritized this area

Company press release: ID:nGNE9p8jD9

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
DKK 142.3 mln
Q3 EBITDA
DKK 84.5 mln
Q3 EBITDA Margin
59.00%


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Chemometec A/S is DKK687.50, about 113.8% above its May 6 closing price of DKK321.60

The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 38 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)